| abstract |
The present invention relates to spiro azepan-oxazolidinones as voltage-gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods of preparing such compounds, methods of preparing novel intermediates useful for their synthesis, and such compositions It relates to a manufacturing method of. The present invention also provides therapeutic effects in the use of such compounds and compositions, particularly in the treatment of inflammatory neuropathy including diabetes mellitus, psoriasis, obesity, transplant rejection, and T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. It relates to their use in administering the compounds and compositions to a patient to achieve this. The compound has a compound of formula (I). Formula 1 In Chemical Formula 1, R 1 , R 2 , R 3 , R 4 , n and m are as defined in the specification. |